title: [Influence of inflammatory bowel disease on pregnancy and fertility - optimal treatment and management].
abstract: Inflammatory bowel diseases (IBD) affect mainly the young population and therefore fertility and pregnancy-related issues are important clinical considerations. Generally, men and women with IBD do not have decreased fertility compared to the general population. Drugs used for IBD do not affect significantly fertility in humans, except sulfasalazine, which causes a temporary reduction in spermatogenesis, but does not reduce fertility itself. The disease course during pregnancy and the risk of pregnancy-related complications depend mainly on the disease activity at the time of conception, therefore, pregnancy should be planned during a phase of remission. Except for methotrexate, mycophenolate mofetil and thalidomide, which are strongly contraindicated, drugs used for IBD appear safe in pregnancy, if they are administered carefully. The highest degree of safety was proved for 5-ASA- -containing agents, thiopurines and corticosteroids. The use of TNFα agents remains disputable, especially in the third trimester of pregnancy, due to their high concentration in the infant`s blood and the lack of data concerning its long-term safety. Surgery, if necessary, should be delayed if possible, although pregnancy is not a contraindication for surgical procedures. The management of IBD in reproductive age and pregnant women remains still controversial, because literature data comes mostly from retrospective studies. The aim of this paper was to summarize and to present proper management of patients with IBD prior to conception, as well as pregnant women and breast-feeding mothers with IBD, based on current European Crohn's and Colitis Organisation (ECCO) guidelines and available literature.
authors.affiliation: Klinika Gastroenterologii, Hepatologii i Zaburzeń Odżywiania, Instytut Pomnik Centrum Zdrowia Dziecka, Warszawa. j.kierkus@czd.pl
authors.forename: Jarosław
authors.initials: J
authors.lastname: Kierkuś
authors.forename: Edyta
authors.initials: E
authors.lastname: Szymańska
authors.forename: Sylwia
authors.initials: S
authors.lastname: Szymańska
authors.forename: Ewa
authors.initials: E
authors.lastname: Kamińska
mesh_terms: D001942:Breast Feeding; D005260:Female; D005298:Fertility; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies; D013091:Spermatogenesis / Q000187:drug effects; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D005765:Gastrointestinal Agents; D012460:Sulfasalazine